World's Best Scientists 2026 revealed!
Award Badge
Medicine
Korea
2026

D-Index & Metrics

Medicine

D-Index
108
Citations
77377
World Ranking
5862
National Ranking
8

Seock-Ah Im publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Seock-Ah Im sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 968 publications — 93rd percentile

93% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Seock-Ah Im D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Seock-Ah Im sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 108 D-Index — 71st percentile

71% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2026 - Research.com Medicine in Korea Leader Award
  • 2025 - Research.com Medicine in Korea Leader Award

Overview

Seock-Ah Im is affiliated with Seoul National University Hospital in South Korea. Their research primarily focuses on medicine, with a substantial number of publications in oncology and related biomedical fields. They have contributed extensively to the understanding and treatment of advanced breast cancer and molecular mechanisms underlying various cancers.

The scientist's main fields of study include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Their research spans multiple subfields such as:

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research
  • Genetics
  • Molecular Biology

Main topics covered in their work involve:

  • Advanced Breast Cancer Therapies
  • HER2/EGFR in Cancer Research
  • Breast Cancer Treatment Studies
  • Cancer Treatment and Pharmacology
  • Cancer Immunotherapy and Biomarkers
  • PARP inhibition in cancer therapy
  • Cancer-related Molecular Pathways

Seock-Ah Im has published in the following venues most frequently:

  • Cancer Research
  • Journal of Clinical Oncology
  • Clinical Cancer Research
  • Cancer Research and Treatment
  • Annals of Oncology

Significant recent papers by Seock-Ah Im include:

  • Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer, 2022, New England Journal of Medicine
  • Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial, 2020, The Lancet
  • ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer, 2021, Annals of Oncology
  • Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer, 2022, New England Journal of Medicine
  • Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study, 2020, The Lancet Oncology

Frequent coauthors collaborating with Seock-Ah Im include:

  • Kyung-Hun Lee
  • Joohyuk Sohn
  • Yeon Hee Park
  • Javier Cortés
  • Sung-Bae Kim

Best Publications

  • Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

    Peter Schmid;Stephen Y Chui;Leisha A Emens

  • Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

    José Baselga;Javier Cortés;Sung-Bae Kim;Seock-Ah Im

  • Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

    Mark Robson;Seock Ah Im;Elżbieta Senkus;Binghe Xu

  • Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

    Luca Gianni;Tadeusz Pienkowski;Young Hyuck Im;Laslo Roman

  • Palbociclib and Letrozole in Advanced Breast Cancer

    Richard S. Finn;Miguel Martin;Hope S. Rugo;Stephen Jones

  • Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

    Massimo Cristofanilli;Nicholas C. Turner;Igor Bondarenko;Jungsil Ro

  • Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.

    Norikazu Masuda;Soo-Jung Lee;Shoichiro Ohtani;Young-Hyuck Im

  • Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

    Shanu Modi;Cristina Saura;Toshinari Yamashita;Yeon Hee Park

  • Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.

    Javier Cortes;David W Cescon;Hope S Rugo;Zbigniew Nowecki

  • Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

    Nicholas C Turner;Dennis J Slamon;Jungsil Ro;Igor Bondarenko

  • Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib

    Sae-Won Han;Tae-You Kim;Pil Gyu Hwang;Soohyun Jeong

  • Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3

    Dennis J. Slamon;Patrick Neven;Stephen Chia;Peter A. Fasching

  • Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial

    Debu Tripathy;Seock Ah Im;Marco Colleoni;Fabio Franke

  • Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer

    Seock-Ah Im;Yen-Shen Lu;Aditya Bardia;Nadia Harbeck

  • 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial

    Luca Gianni;Tadeusz Pienkowski;Young Hyuck Im;Ling Ming Tseng

  • ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer†

    A. Gennari;F. André;C.H. Barrios;J. Cortés

  • Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

    Sandra M Swain;Sandra M Swain;David Miles;Sung-Bae Kim;Young-Hyuck Im

  • Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

    Miguel Martin;Frankie A Holmes;Bent Ejlertsen;Suzette Delaloge

  • Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.

    Dennis J. Slamon;Patrick Neven;Stephen Chia;Peter A. Fasching

  • Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial

    Aimery de Gramont;Eric Van Cutsem;Hans Joachim Schmoll;Josep Tabernero

Frequent Co-Authors

Yung-Jue Bang
Yung-Jue Bang Seoul National University
Dae Seog Heo
Dae Seog Heo Seoul National University Hospital
Dong-Wan Kim
Dong-Wan Kim Seoul National University Hospital
Dong-Young Noh
Dong-Young Noh Seoul National University
Sung-Bae Kim
Sung-Bae Kim University of Ulsan
Se-Hoon Lee
Se-Hoon Lee Sungkyunkwan University
Javier Cortes
Javier Cortes Vall d'Hebron Hospital Universitari
Hope S. Rugo
Hope S. Rugo University of California, San Francisco
Nadia Harbeck
Nadia Harbeck Ludwig-Maximilians-Universität München
Woo Kyung Moon
Woo Kyung Moon Seoul National University Hospital

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine in the USA opens the door to a wide spectrum of related healthcare degrees and career pathways you can pursue online. These programs are ideal for those seeking flexibility, career advancement, or a transition into medical fields.

If you're interested in leadership roles within healthcare, healthcare administration programs can provide the management skills required to oversee hospitals and clinics. Similarly, for those aiming for executive positions, consider online mha programs cahme accredited, which are recognized for their industry-standard curricula and accreditation.

Nursing professionals who want to advance can benefit from bridge programs. The adn to fnp programs offer a fast track from an associate’s degree to becoming a family nurse practitioner, opening new clinical and leadership opportunities.

If you’re passionate about preventative health and dietary sciences, an online bachelor's degree in nutrition provides the foundation needed to impact community health as a qualified nutritionist or wellness coach.

Each pathway supports vital roles within healthcare and can be tailored to suit diverse interests and schedules, helping you take the next step in your medical or allied health career.

Best Scientists Citing Seock-Ah Im

Trending Scientists

Recently Published Articles